This was the second week of trading for 2016, and many shareholders were affected this week as we saw broad markets, oil prices and China crumble. Both the Dow Jones Industrial Average and S&P 500 felt an impact from China only late in the week, but there was ongoing weakness from oil the entire week. Some companies absolutely destroyed shareholders, for multiple reasons, and the broad markets help give that extra push down.

While these were not the five biggest absolute losers of the week, of the active stocks, these all issued news or had news that took place and pushed the stocks down. 24/7 Wall St. has tracked five companies in which shareholders were punished last week. We have specifically avoided companies within the energy and commodities sectors.

Sarepta Therapeutics

While Sarepta Therapeutics Inc. (NASDAQ: SRPT) plunged early on Friday, it was not on news that it has done anything wrong or failed any clinical trials. Sarepta retreated as the result of a failed clinical trial by BioMarin Pharma.

On Thursday, the U.S. Food and Drug Administration (FDA) turned down a New Drug Application (NDA) for BioMarin’s treatment of Duchenne muscular dystrophy (DMD). Sarepta is developing its own treatment for DMD, a drug called eteplirsen, which will face an FDA review on Friday January 22. The FDA will give its decision by February 26.

What we’re seeing here is investors getting spooked by a failed study within one major biotech and thinking this could very well happen to the other. However, the fallout from this failed study within Sarepta is much more crippling than in BioMarin.

Over the course of the week, Sarepta shares fell 60% and, and year to date they are down 62.7%. Shares traded at $14.28 on Friday’s close. The stock has a consensus analyst price target of $46.75 and a 52-week trading range of $11.42 to $41.97.

Celgene

A business update sank Celgene Corp. (NASDAQ: CELG) in Monday’s session, though this investor sentiment could be misplaced. The update was largely in line with analyst expectations. At JPMorgan’s 34th Annual Healthcare Conference, Celgene noted that it expects net product sales for 2016 to be roughly $10.5 billion to $11.0 billion, and earnings per share (EPS) are expected to be in the range of $5.50 to $5.70. Thomson Reuters has consensus estimates that call for $11.13 billion in revenue and $5.68 in EPS for the full year.

Apart from this, a negative impact from foreign exchange rates is expected to be approximately $120 million in 2016. Also full-year sales of Revlimid are expected to be in the range of $6.6 billion to $6.7 billion.

Shares fell 5.3% last week and are down nearly 14% year to date. The stock ended last week at $103.06. The consensus analyst price target is $142.67, and the 52-week trading range is $92.98 to $140.72.
GoPro

GoPro Inc. (NASDAQ: GPRO) has reported certain preliminary financial results for the fourth quarter. This stock has been on the long way down after it debuted on the market in 2013. Shares were above $90 at one point, but since then they have slowly declined to the current price level. The stock has been pushing lower lows, well below the IPO price, so a technical bounce might be out of the question, and calling a bottom now might not be realistic.

The company expects revenue to be roughly $435 million for the fourth quarter of 2015 and $1.6 billion for the calendar year. The consensus estimates from Thomson Reuters call for $511.87 million in revenue in the fourth quarter and $1.69 billion in revenue for the calendar year.

In the past week, the stock dropped 29.4%. Shares of GoPro were trading at $11.46 on Friday’s close, with a consensus price target of $18.35 and a 52-week range of $11.23 to $65.49.

SunEdison

Since the beginning of this year, SunEdison Inc. (NYSE: SUNE) has taken an absolute beating, and the end of 2015 was not that good either. The company now faces a lawsuit from Appaloosa Management. Specifically, Appaloosa is suing TerraForm Power for taking over some assets owned by Vivint Solar. Even last week, SunEdison faced serious problems when it announced the restructuring of its debt, and investors did not take kindly to this.

Over the course of this week, the stock fell 18.5%, and since the beginning of the year shares are down 45.4%. SunEdison traded at $2.74 on Friday’s close, with a consensus price target of $13.67 and a 52-week range of $2.36 to $33.45.

Best Buy

Best Buy Co. Inc. (NYSE: BBY) was a leader in the market with one of the best performances out of the major retail stocks but this was in 2014. This past holiday season was very much the opposite. The retail giant reported its results for the nine weeks ended January 2, 2016, and they failed to impress.

Domestic revenue of $10.1 billion decreased 0.8% from last year. This decrease was primarily driven by a comparable sales decline of 1.4%. Domestic online revenue of $1.7 billion increased 12.6% on a comparable basis, primarily due to a higher conversion rate. As a percentage of total domestic revenue, online revenue increased 200 basis points to 16.7% from 14.7% last year.

The stock fell 6.2% last week, and shares are down 10.8% year to date. The landed at $27.11 when Friday’s session came to a close, within a 52-week trading range of $25.37 to $42.00. The consensus price target is $36.94.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.